University Hospital of Heidelberg, Department of Radiation Oncology
Welcome,         Profile    Billing    Logout  
 19 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Debus, Juergen
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
Rieken, Stefan
PACCELIO, NCT06102057 / 2022-003408-33: - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting
2
110
Europe
standard Radiotherapy, standard, Chemotherapy, Immunotherapy, Experimental Radiotherapy, Experimental
TheraOp, AstraZeneca
Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
06/26
06/28
Shafie, Rami El
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PACCELIO, NCT06102057 / 2022-003408-33: - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting
2
110
Europe
standard Radiotherapy, standard, Chemotherapy, Immunotherapy, Experimental Radiotherapy, Experimental
TheraOp, AstraZeneca
Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
06/26
06/28

Download Options